NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis $2.14 -0.13 (-5.55%) As of 10:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsSEC Filings About Artelo Biosciences Stock (NASDAQ:ARTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artelo Biosciences alerts:Sign Up Key Stats Today's Range$2.25▼$2.4050-Day Range$2.17▼$7.3152-Week Range$2.05▼$179.19Volume10,106 shsAverage Volume293,871 shsMarket Capitalization$1.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a biological signaling network involved in areas such as pain, appetite, inflammation and cancer. The company’s programs are designed to address unmet medical needs in oncology and other therapeutic areas. Artelo’s development pipeline has included ART27.13, a peripherally restricted cannabinoid receptor type 1 agonist being investigated for cancer-related anorexia and cachexia. The company has also developed ART26.12, a selective fatty acid-binding protein 5 inhibitor with potential applications in oncology and pain, and ART12.11, a proprietary cannabidiol-based therapeutic candidate. The company was established in 2011 and is headquartered in San Diego, California. Artelo has conducted research and development activities in collaboration with organizations in the United States and the United Kingdom. Its leadership has included Gregory D. Gorgas, who has served as president and chief executive officer.AI Generated. May Contain Errors. Read More Artelo Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreARTL MarketRank™: 0.607708836955 of 5 starsArtelo Biosciences scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingArtelo Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Artelo Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Artelo Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.55% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently decreased by 24.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentArtelo Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Artelo Biosciences this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.20% of the stock of Artelo Biosciences is held by insiders.Percentage Held by Institutions0.87% of the stock of Artelo Biosciences is held by institutions.Read more about Artelo Biosciences' insider trading history. Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTL Stock News HeadlinesArtelo Biosciences (NASDAQ:ARTL) Shares Down 5.4% - Should You Sell?November 5 at 4:02 AM | americanbankingnews.comArtelo Biosciences consensus price target increased 2,600% to $826.20November 2 at 6:37 AM | msn.comThe government is buying stocksDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 5 at 1:00 AM | Porter & Company (Ad)Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on PainOctober 29, 2026 | globenewswire.comArtelo Biosciences to Present ART26.12 Data at IASP World Congress on Pain as First Selective FABP5 Inhibitor Advances Toward MAD StudyOctober 26, 2026 | quiverquant.comQArtelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on PainOctober 26, 2026 | globenewswire.comArtelo Biosciences To Feature First Clinical Results For ART26.12 At BIO-EuropeOctober 7, 2026 | rttnews.comArtelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor PlatformOctober 7, 2026 | globenewswire.comSee More Headlines ARTL Stock Analysis - Frequently Asked Questions How have ARTL shares performed this year? Artelo Biosciences' stock was trading at $32.94 at the start of the year. Since then, ARTL shares have decreased by 93.0% and is now trading at $2.3090. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) posted its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($6.48) by $5.59. When did Artelo Biosciences' stock split? Artelo Biosciences shares reverse split on the morning of Tuesday, March 10th 2026.The 1-3 reverse split was announced on Friday, March 6th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 9th 2026. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Artelo Biosciences IPO? Artelo Biosciences (ARTL) raised $80,000 in an IPO on Friday, June 21st 2019. The company issued 8,000,000 shares at a price of $0.01 per share. How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include NIO (NIO), Ford Motor (F), FuelCell Energy (FCEL), Hepion Pharmaceuticals (HEPA), SNDL (SNDL), Tonix Pharmaceuticals (TNXP) and Tesla (TSLA). Company Calendar Last Earnings8/12/2026Today11/05/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ARTL's financial health is in the Red zone, according to TradeSmith. ARTL has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARTL CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)($151.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-518.27% Return on Assets-194.29% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio3.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($17.03) per share Price / Book-0.14Miscellaneous Outstanding Shares550,000Free Float530,000Market Cap$1.27 million OptionableNot Optionable Beta0.01 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ARTL) was last updated on 11/5/2026 by MarketBeat.com Staff. From Our PartnersThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredTrump compared today's market to 1929 not once but twicePresident Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored$250,000/Month- How You Can Learn from President TrumpPresident Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get a...The Oxford Club | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARTL Stock Alerts